Skip to main content

August 10, 2021

Top Stories

Research

Revive Therapeutics Provides Update on Psychedelics Clinical Product Pipeline

MarketWatch

The Company is working with the Board of Regents of the University of Wisconsin System under a clinical trial agreement to conduct a Phase I/II clinical study to evaluate the safety and feasibility of psilocybin in adults with methamphetamine use disorder. Study start-up activities have taken place and enrollment activities are to continue throughout the remainder of the year. As a result of the study, clinical data will provide proprietary and valuable information on the safety, efficacy and dosing of psilocybin to support future pivotal FDA clinical studies in oral forms of delivery including oral thin film strips. The clinical study will be conducted at the University of Wisconsin-Madison, School of Medicine and Public Health and School of Pharmacy, which holds a Wisconsin special authorization and DEA license to perform clinical research with psilocybin.

Athletics

UW Experts in the News

School districts in lower transmission areas navigate CDC, DPI mask guidance ahead of school year

WKOW-TV 27

Health experts maintain that even if there is lower transmission in an area, students should be masked.”Six or seven or eight hours is a big chunk of the day,” said Dr. Ellen Wald, chair of pediatrics at the UW School of Medicine. “It’s a time when they’re in close proximity with 20 to 30 other children in a single room. That doesn’t happen in the rest of the day.”

UW-Madison Related